FDAFDA PCAC reviews BPC-157, KPV, TB-500, MOTS-c (Jul 23) and DSIP, Semax, Epitalon (Jul 24, 2026) for 503A compounding eligibilityUPDATESemaglutide and tirzepatide compounding ended — shortage resolved Feb/May 2025REGULATORY12 peptides removed from FDA Category 2 (Apr 23, 2026) — removal is not approval; all remain pending PCAC reviewREGULATORYNo formal FDA reclassification published — no restricted peptide is legal to compound; 5 more peptides go to PCAC before Feb 2027RESEARCHA Real-world Study of Treatment Retention and Adherence to Secukinumab in Patients With Plaque Psoriasis (PsO) With or Without Glucagon-like Peptide-1 Receptor Agonist (GLP-1 RA) Co-therapy [NCT07881783]RESEARCHStudy to Evaluate the Dose-Dependent Effect of Tirzepatide on Gastric Emptying in Adult Patients With Type 1 Diabetes [NCT07951658]RESEARCHA Study of Investigational Tirzepatide (LY3298176) Doses in Participants With Type 2 Diabetes and Obesity [NCT06037252]RESEARCHA Study to Learn About the Study Medicine Called Rimegepant in Adults When Used for the Prevention of Chronic Migraine [NCT07729462]RESEARCHHypersensitivity to Amylin in Post-Traumatic Headache [NCT07340775]RESEARCHEffects of Tirzepatide on Corneal Nerve Morphology and Other Ocular Parameters in Adults With Obesity [NCT07950371]NEWSSTAT+: Peptide market poised to explode with new Hims and Noom launchesRESEARCHAlleviating Carbohydrate Counting for Patients With Type-1 Diabetes Using a Closed Loop System With Weekly Subcutaneous Semaglutide [NCT06387199]RESEARCHWeight Trajectories and Predictive Factors After Semaglutide in Patients With Grade 3 and Complicated Obesity [NCT07423481]RESEARCHSEMAFORCRANIO : Multicenter, Double-blind, Parallel, Randomized Controlled Trial of the Efficacy of Semaglutide in Hypothalamic Obesity Secondary to Craniopharyngioma in Children Aged 12 to 17 Years [NCT07845994]FDAFDA PCAC reviews BPC-157, KPV, TB-500, MOTS-c (Jul 23) and DSIP, Semax, Epitalon (Jul 24, 2026) for 503A compounding eligibilityUPDATESemaglutide and tirzepatide compounding ended — shortage resolved Feb/May 2025REGULATORY12 peptides removed from FDA Category 2 (Apr 23, 2026) — removal is not approval; all remain pending PCAC reviewREGULATORYNo formal FDA reclassification published — no restricted peptide is legal to compound; 5 more peptides go to PCAC before Feb 2027RESEARCHA Real-world Study of Treatment Retention and Adherence to Secukinumab in Patients With Plaque Psoriasis (PsO) With or Without Glucagon-like Peptide-1 Receptor Agonist (GLP-1 RA) Co-therapy [NCT07881783]RESEARCHStudy to Evaluate the Dose-Dependent Effect of Tirzepatide on Gastric Emptying in Adult Patients With Type 1 Diabetes [NCT07951658]RESEARCHA Study of Investigational Tirzepatide (LY3298176) Doses in Participants With Type 2 Diabetes and Obesity [NCT06037252]RESEARCHA Study to Learn About the Study Medicine Called Rimegepant in Adults When Used for the Prevention of Chronic Migraine [NCT07729462]RESEARCHHypersensitivity to Amylin in Post-Traumatic Headache [NCT07340775]RESEARCHEffects of Tirzepatide on Corneal Nerve Morphology and Other Ocular Parameters in Adults With Obesity [NCT07950371]NEWSSTAT+: Peptide market poised to explode with new Hims and Noom launchesRESEARCHAlleviating Carbohydrate Counting for Patients With Type-1 Diabetes Using a Closed Loop System With Weekly Subcutaneous Semaglutide [NCT06387199]RESEARCHWeight Trajectories and Predictive Factors After Semaglutide in Patients With Grade 3 and Complicated Obesity [NCT07423481]RESEARCHSEMAFORCRANIO : Multicenter, Double-blind, Parallel, Randomized Controlled Trial of the Efficacy of Semaglutide in Hypothalamic Obesity Secondary to Craniopharyngioma in Children Aged 12 to 17 Years [NCT07845994]

研究用のみ。 完全な免責事項 →

研究/Real-World Efficacy of Tirzepatide in Paraguay: A Prospective Study on Obesity and Type 2 Diabetes
研究ライブラリに戻る

Real-World Efficacy of Tirzepatide in Paraguay: A Prospective Study on Obesity and Type 2 Diabetes

May 25, 2026
Share
発展中の研究

これらは有望ですが、さらなる検証が必要な発展途上の見解に基づいています。

この分析について

この記事は、最近のニュースアイテムや臨床試験リストのAI補助要約です。ペプチド研究コミュニティにとって迅速でアクセスしやすい概要を提供することを目的としています。正確性のために常に下記リンク先の元のソースをご確認ください。

Real-World Efficacy of Tirzepatide in Paraguay: A Prospective Study on Obesity and Type 2 Diabetes

In a significant development for peptide research, a new study has begun to assess the effectiveness and safety of tirzepatide, a promising therapy for obesity and type 2 diabetes mellitus (T2DM), under real-world conditions in Paraguay. The trial, sponsored by Las Rías Medical Center, aims to provide valuable insights into how this medication performs outside of controlled clinical settings.

Background

Peptide therapies have gained considerable attention in recent years due to their potential in managing complex health issues like obesity and T2DM. Tirzepatide, a glucagon-like peptide-1 (GLP-1) receptor agonist and a glucose-dependent insulinotropic polypeptide (GIP) receptor agonist, has shown promising results in clinical trials for weight management and diabetes control. However, its efficacy under real-world conditions remains largely unexplored.

This new study is set to bridge this gap by evaluating tirzepatide’s performance among patients who are receiving the drug as part of their regular treatment regimen. The research will focus on two distinct cohorts: one consisting of adults with obesity without T2DM and another including those with T2DM, regardless of whether they also have obesity.

Key Details

The prospective cohort study involves a total of 160 participants from Paraguay, divided equally into the two cohorts. Each participant in both groups will receive tirzepatide as part of their standard clinical care and will be monitored for a period that is yet to be specified by the researchers. The primary objectives of the trial are to assess the drug’s efficacy, safety, and tolerability.

The study, which is currently recruiting participants, is being conducted under the Phase 4 classification, indicating it focuses on post-marketing surveillance and long-term effects. Such studies play a crucial role in validating clinical outcomes seen during earlier phases of research and provide essential data for regulatory bodies like the FDA to refine guidelines and recommendations regarding peptide therapies.

Key Takeaways

  • Real-world Evidence: The study aims to gather critical real-world evidence on tirzepatide's efficacy and safety, which is vital for understanding how patients might respond in everyday clinical settings.
  • Patient Diverse Demographics: By including both obesity-only cases and those with T2DM, the research offers a comprehensive view of the drug’s effectiveness across different patient profiles.
  • Standard Clinical Care Setting: Participants will receive tirzepatide as part of their usual treatment protocols, offering insights into how well the therapy integrates into existing healthcare practices.
  • Long-term Monitoring: The study's focus on long-term outcomes provides valuable data for assessing sustained benefits and any potential side effects over extended use periods.

What This Means

For the peptide research community, this trial represents a significant step forward in understanding the practical implications of using tirzepatide. As more studies like these emerge, healthcare providers will have better guidance on how to effectively incorporate such therapies into patient care plans. Moreover, it underscores the importance of real-world data in validating clinical outcomes and ensuring that therapeutic options are as effective and safe as initial research suggests.

The findings from this study could also influence future regulatory decisions and contribute to improved treatment protocols for obesity and T2DM, benefiting millions globally who struggle with these conditions daily.

---

Source: ClinicalTrials.gov — Published 2026-05-19

This article is for informational purposes only and does not constitute medical advice.

編集者の注

この分析はAIツールを使用して生成され、Peptide Contacts編集部がレビューしました。正確性を追求していますが、AI生成のコンテンツには誤りや省略がある可能性があります。情報確認のために常に元のソースをご確認ください。 元のソース 詳細、方法論、データについては

Peptide Contactsは、情報提供のために-curated研究要約を提供しています。このコンテンツは医療アドバイスにはなりません。健康決定をする前に常に格付けされた医療専門家に相談してください。

Comments

Sign in to join the discussion

この記事はAIを使用して生成され、誤りや省略がある可能性があります。情報提供のために提供されていますが、医療アドバイスにはなりません。常に元のソースを確認し、格付けされた医療専門家に相談してください。